Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
Frontiers in Molecular Neuroscience, 2018 Until now, the dopamine (DA) precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), remains the gold standard effective drug therapy for Parkinson’s disease (PD) patients.
Di-Sheng Lu +7 more
doaj +1 more source
Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease [PDF]
, 2017 Although intrastriatal transplantation of fetal cells for the treatment of Parkinson’s disease had shown encouraging results in initial open-label clinical trials, subsequent double-blind studies reported more debatable outcomes.
Breger, Ludivine S. +4 more
core +2 more sources
L-Dopa and Schizophrenia [PDF]
Canadian Psychiatric Association Journal, 1976 Previous reports have emphasized the deterioration of schizophrenic patients when given L-Dopa. The authors described a patient with long-standing catatonic schizophrenia who was not helped by conventional therapies but initially responded dramatically to L-Dopa. Placebo substitution resulted in worsening of her condition but restarting the L-Dopa did
P E, Garfinkel, H C, Stancer
openaire +2 more sources
Frontiers in Behavioral Neuroscience, 2014 Bradykinesia (slowness of movement) and other characteristic motor manifestations of Parkinson’s disease (PD) are alleviated by treatment with L-dihydroxyphenylalanine (L-DOPA).
Stefania eSgroi +3 more
doaj +1 more source
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats [PDF]
, 2017 In addition to its role in neuronal survival, the brain neurotrophic factor (BDNF) has been shown to influence serotonin transmission and synaptic plasticity, events strongly implicated in the appearance of l-DOPA-induced dyskinesia (LID), a motor ...
Björklund, Anders +7 more
core +1 more source
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations [PDF]
, 2014 In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin neurons possess the enzymatic machinery able to convert exogenous l-DOPA
CARTA, MANOLO, TRONCI, ELISABETTA
core +1 more source
Neurobiology of Disease, 2010 Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles +3 more
doaj +1 more source
Implanted Reuptake-deficient or Wild-type Dopaminergic Neurons Improve ON L-dopa Dyskinesias Without OFF-dyskinesias in a Rat Model of Parkinson's Disease [PDF]
, 2012 OFF-L-dopa dyskinesias have been a surprising side-effect of intrastriatal foetal ventral mesencephalic transplantation in patients with Parkinson's disease.
Caron, M. G. +7 more
core +1 more source
Evidence of
Journal of Biomedical Science, 2010 Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li +5 more
doaj +1 more source
Treatment of periodic leg movements with a dopaminergic agonist in subjects with total spinal cord lesions [PDF]
, 1999 Objective: To investigate the effect of L-dopa on the PLM/h index of spinal cord injured subjects.Setting: São Paulo, Brazil.Methods: Thirteen male volunteers with spinal cord section between T7-T12, and mean age of 31.6 +/- 8.3 years participated in the
Mello, Marco Tulio de +2 more
core +2 more sources